RARE/MREO: ORBIT UX143 P2 improvements NOT solely due to natural progress seen with age

 Ahead of Ultragenyx's [RARE] 4Q25 ORBIT Osteogenesis Imperfecta setrusumab phase III, our comprehensive report reveals phase II improvements in bone density and fracture reduction are unlikely attributable solely to the natural improvement in osteogenesis with age but are likely due to setrusumab...